IGC, Inc. (NYSE-MKT: IGC) announces the third vertical in its
effort to gain a leading position in the emerging legal cannabis
industry. Our strategy is to develop a product portfolio of
phytocannabinoid-based therapies for the treatment of a wide range
of therapeutic indications including pain, epilepsy, and other
niche severe terminal diagnosis, which are life altering or life
threatening. Most recently, the company applied for a provisional patent
based on a novel therapy that uses cannabinoid extracts for the
treatment of seizures in dogs and cats. The therapy, which is
expected to also have applications in humans, is administered using
a variety of delivery technologies. We expect to establish
metabolic profiling and apply to the FDA for trials.To facilitate the development of the product portfolio, IGC is
entering into partnerships with a range of organizations that can
provide cost effective solutions for metabolic profiling, clinical
trials, and regulatory approvals that in most cases will be
necessary to eventually commercialize our products."The Company is also continuing to assemble an international
network of doctors, veterinarians, and researchers with extensive
expertise in various indications, medicines containing controlled
substances, plant-based products, extraction technologies, and drug
delivery technologies. In addition, we have assembled experts
in patent law, clinical trials, and regulatory procedures," said
Ram Mukunda, IGC's CEO.Mukunda added,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in